A strategic shift, not just a trend
In 2024, the L’Oréal group – via its Bold private equity fund – acquired a minority stake in Timeline, a biotech company specializing in the science of longevity. Two years later, Lancôme followed suit with the launch of a range of skincare products incorporating Mitopure, marking the first large-scale global deployment of this technology by a major cosmetics brand.
Timeline: fifteen years of cell research
Founded by Patrick Aebischer, former President of the École polytechnique fédérale de Lausanne (EPFL), and Chris Rinsch, PhD in cell and molecular biology, Timeline has established itself in just a few years as one of Europe’s most visible biotechs in the field of cell longevity research.
Its flagship technology, Mitopure, is a highly purified form of Urolithin A, a postbiotic touted as capable of reactivating mitochondria – the energy powerhouses of cells – via a renewal mechanism known as “mitophagy”. The molecule, the result of over fifteen years’ research, backed by several clinical studies, over 50 worldwide patents and more than $50 million invested in R&D, counts giants such as Nestlé and L’Oréal among its investors.
Buoyed by growing popularity, Timeline inaugurated its first pop-up in New York at the end of 2025, with sales simply tripling in one year.
A new range designed for “visible biological ageing”.
For this collaboration, Lancôme brings its expertise in skin biology, formulation and diagnostics, while Timeline contributes its know-how in longevity science with Mitopure, initially developed for oral nutritional supplements.
The new products – still confidential – will be what Vania Lacascade, Global President of Lancôme, describes as “high-performance, sensorial luxury formulas”, designed to act on the skin’s biological age. The range will be officially presented at the American Academy of Dermatology’s annual meeting, March 27-29, 2026, in Denver, Colorado.
A paradigm shift in the beauty industry
What’s striking about this partnership is the philosophy behind it. Vania Lacascade emphasizes a radical shift in approach: “It’s no longer just about correcting what’s visible, but acting on biological mechanisms to preserve and restore skin health over time.”
Lacascade speaks of a shift from “corrective and reactive” skincare to “proactive and data-driven” skincare. A vision best summed up by this sentence: “Longevity is a frontier of radical scientific progress, and we believe it will shape the future of beauty. It fully corresponds to what women want today: to live better, not just longer.”
From Timeline’s point of view, the partnership is seen as an opportunity to change scale. Chris Rinsch, co-founder and president, sees the alliance as a turning point: “This partnership represents a unique opportunity to democratize our Mitopure longevity molecule, making its advanced benefits more widely accessible than ever before.”
A three-pillar Longevity Integrative Science strategy
This is not an isolated launch. The integration of Timeline is part of Lancôme’s “Longevity Integrative Science” strategy, which is based on three pillars. In 2025, the brand launched Absolue Longevity The Soft Cream, powered by Absolue PDRN technology. It also developed Cell BioPrint, a “lab-on-a-chip” skin analysis solution in partnership with Korean startup NanoEnTek, using proteomics to determine the skin’s biological age.
With Mitopure, the third pillar is in place: direct action on cell renewal at the mitochondrial level.
What this reveals about the new rules of the luxury game
This partnership illustrates several of the transformation dynamics we are seeing in the luxury and beauty industries.
Firstly, upstream investment as a competitive advantage: by acquiring a stake in Timeline in 2024 via Bold, L’Oréal has secured exclusive access to a breakthrough technology ahead of its competitors. The acquisition of a stake precedes the product launch – this is the logic of a company that thinks in terms of ecosystems, not just catalogs.
Secondly, scientific proof is the new language of luxury: where anti-aging was once sold on sensorial promises and aspirational images, it is now built on clinical trials, patents and biological data. Consumers – and in particular the 40-65 year-old women targeted by these ranges – are increasingly demanding proof.
Finally, biotech-beauty collaboration as a model for innovation: Lancôme does not develop Mitopure in-house. It partners with those who master the science, to bring what only it possesses: luxury formulation, worldwide distribution, brand desirability. It’s a form of collective intelligence that redefines R&D in the major brands.
The beauty industry is entering an era in which cell biology is becoming a field of strategic differentiation. Those who can forge the right scientific alliances – and translate them into desirable consumer experiences – will lay the foundations for tomorrow’s luxury beauty.
